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Abstract
Background: Various molecular-targeting therapies have become available for the treatment of advanced renal cell
carcinoma (RCC). Accurate prognostication is desirable for choosing the appropriate treatment for individual patients.
18F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is a non-invasive tool
for evaluating glucose accumulation, which can be an index of biological characteristics of cancer. We prospectively
evaluated FDG PET/CT as a prognostic indicator in patients with advanced RCC.
Methods: A total of 101 patients slated for different systematic therapies for advanced RCC were enrolled between
2008 and 2014. A total of 61 patients had recurrent RCC (58 metastatic and 3 regional) and 40 patients had stage IV
RCC (36 metastatic and 4 locoregional). Sixteen patients had not undergone nephrectomy. Pre-treatment FDG PET/CT
was performed, and the max SUVmax (the highest SUV measurement in each patient) was recorded. The max SUVmax
was compared with different clinical risk factors as prognostic indicators. The median observation period was
18 months (range 1–70 months).
Results: The max SUVmax of the 101 subjects ranged from undetectable to 23.0 (median 6.9). Patients with high max
SUVmax had a poor prognosis. Multivariate analysis with standard risk factors revealed that max SUVmax was an
independent predictor of survival (p < 0.001; hazard ratio 1.265; 95 % confidence interval 1.159–1.380). A cutoff of 8.8
for max SUVmax advocated in our previous report was highly significant (p < 0.0001). When we subclassified the max
SUVmax values, the median overall survival of subjects with max SUVmax < 7.0 was 41.9 months. That of subjects with
max SUVmax between 7.0 and 12.0 was 20.6 months. That of subjects with max SUVmax≥ 12.0 was 4.2 months. The
differences were statistically significant.
Conclusions: Pretreatment max SUVmax assessed by FDG PET/CT is a useful prognostic marker for patients with
advanced RCC, providing helpful information for clinical decision making.
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Background
Renal cell carcinoma (RCC) accounts for 3 % of all
adult cancers [1]. Approximately 30 % of RCC patients
are diagnosed with metastases, and an additional 20–
40 % develop metastases after radical nephrectomy with
curative intent [2, 3]. Cytokine therapies have been the
only treatments available for advanced RCC for a long
time, and have been associated with a disappointing
outcome [4, 5]. With elucidation of the oncogenic
mechanisms of RCC, however, agents that target critical
molecules in the biological pathways necessary for
oncogenesis, such as vascular endothelial cell growth
factor or the mammalian target of rapamycin (mTOR),
have been developed. These molecular-targeting thera-
peutics have improved outcomes for patients with ad-
vanced RCC [6–9], and are recommended as the main
treatments for advanced RCC in clinical guidelines ap-
plied worldwide [10, 11].
It is well known that prognoses for patients with RCC
can vary, and the guidelines recommend risk-directed
therapies using prognostic classifications based on a
combination of clinical information and laboratory data
[8, 10, 11]. The Memorial Sloan-Kettering Cancer Cen-
ter (MSKCC) classification using five clinical factors in-
cluding performance status, the interval from diagnosis
to start of treatment, lactate dehydrogenase (LDH), cor-
rected calcium, and anemia, is most commonly used for
prognosis [12]. These clinical parameters are thought
to express the biological activity of RCC indirectly.
However, in this era of molecular-targeting therapy, an
index that expresses the biological activity of RCC
directly, and prognosticates accurately, is desired for
appropriate clinical decision making.
18F-2-fluoro-2-deoxyglucose positron emission
tomography-computed tomography (FDG PET/CT) is
a useful non-invasive tool for evaluating glucose meta-
bolic status, which can be an index of the biological ac-
tivity of cancer. We focused on standardized uptake
value (SUV), a quantitative simplified measure of tissue
FDG accumulation, and previously reported that max
SUVmax (i.e., the highest SUV of all RCC lesions in
each patient) predicted the overall survival (OS) of pa-
tients with advanced RCC [13]. In that paper, we re-
ported that the survival of patients with max SUVmax
greater than or less than the cutoff value of 8.8 were
statistically different (p=0.0012). Subsequently, Kayani
reported that high SUVmax correlated with shorter
overall survival in patients treated with the tyrosine
kinase inhibitor (TKI) sunitinib [14]. Chen reported
that baseline SUVmax correlated with the overall sur-
vival of patients with RCC treated by everolimus, which
is an oral mTOR inhibitor (mTORI) [15]. Other investi-
gators also advocated the usefulness of FDG PET/CT as
a prognostic tool for patients with RCC [16, 17].
In this study, we report results from an expanded
number of patients and a longer follow-up period.
Methods
Patients
This was a prospective study that followed enrolled pa-
tients slated to undergo systemic therapies for patho-
logically proven advanced RCC between June 2008 and
January 2014. The patients were initially assessed by
conventional imaging techniques (computed tomography,
magnetic resonance imaging, or bone scintigraphy) and
diagnosed as stage IV or recurrent RCC. Patients with
uncontrolled diabetes mellitus (fasting blood sugar >
150 mg/dL), other known malignancies, and patients who
had received treatment within 2 weeks prior to enroll-
ment were excluded. The study protocol was approved
by the Yokohama City University Institutional Review
Board. Written informed consent was obtained from all
patients.
Initially, 110 patients were enrolled in the study.
Nine were eventually eliminated: four whose pathology
could not be confirmed conclusively, three who de-
cided against treatment after evaluation by FDG PET/
CT, one patient had a fasting blood sugar over
150 mg/dL, and one with contralateral kidney metasta-
ses for which accurate SUV could not be measured
owing to the urinary excretion of the radiotracer. This
left a total of 101 patients for the analysis, including 24
who had been analyzed in the preliminary report [12].
The first therapeutic interventions after enrollment in
this study were decided before the evaluation by FDG
PET/CT.
Imaging
Patients fasted for at least 6 h prior to intravenous in-
jection of 18F FDG. PET/CT images were acquired
(Aquiduo 16®; Toshiba Medical Systems, Tokyo, Japan).
One hour after injection of 2.5 MBq/kg of 18F FDG,
PET/CT images were acquired from the top of the head
to the mid-thigh. A low-dose, non-contrast CT scan
was acquired first and used for attenuation correction.
Emission images were acquired in three-dimensional
mode for 2 min per bed position. After PET acquisition,
contrast-enhanced CT was performed with a 2-mm
section thickness, 120 kV, 400 mA, 0.5 s/tube rotation,
from the top of the head to the mid-thigh, with breath
holding. A total of 100 mL contrast medium (iopamidol)
was administered intravenously at a rate of 1.0 mL/s. The
scan delay was set at 120 s after the start of the injec-
tion of contrast material. Patients with serum creatinine
levels > 1.5 mg/dL were examined without contrast ma-
terial. The all cases with origin RCC were evaluated by
contrast enhanced CT scan. Images were reconstructed
by attenuation-weighted, ordered-subset expectation
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maximization (four iterations, 14 subsets, 128 × 128
matrix, with 5-mm Gaussian smoothing). The SUV was
determined according to the standard formula, with ac-
tivity in the volume of interest (VOI) recorded as Bq
per mL/injected dose in Bq per total body weight (kg).
VOIs were positioned to encompass targets within
areas of increased uptake and measured on each slice
by two experienced physicians (DU and KM), who were
blinded to clinical data. Discrepancies were resolved by
consensus reading. Analysis of FDG uptake in the primary
tumor was made with reference to contrast-enhanced CT
images to differentiate tumor from physiologic parenchy-
mal and urinary tract activity. The maximum activity of all
VOIs of each patient was defined as the max SUVmax.
Statistical analysis
Survival time was calculated from the date of evaluation
by 18F-FDG PET/CT to the date of death. A Cox pro-
portional hazards model was used to assess the effects of
max SUVmax on survival. OS curves were estimated by
the Kaplan-Meier method, and the resulting curves were
compared using the log-rank test. The impacts on over-
all survival (OS) of max SUVmax and other standard
clinicopathologic factors (performance status, the inter-
val from diagnosis to start of treatment, LDH, corrected
calcium, age, sex, and pathology) were analyzed by a uni-
variate Cox hazard model, and the factors with p < 0.05
were analyzed by a multivariate Cox hazard model. All
statistical analyses were carried out with commercial
software (SPSS®, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The characteristics of the 101 patients are shown in
Table 1. Of 40 patients with Stage IV disease, 24 had not
undergone prior nephrectomy. The FDG PET/CT evalu-
ation of the 17 patients who had received prior therapy
was performed more than 2 weeks after the end of any
previous treatment.
Table 1 Patients characteristics
Characteristic No. of patients (%)





Median (Range) 65 (32–82)
Pathology
Clear cell 86 (85)
Papillary 6 (6)

























Table 2 Interventions after PET/CT evaluation
Interventions No. of patients (%)





2 interventions 22 (22)
TKI to mTORI 10
TKI to TKI 9
mTORI to TKI 3
3 interventions 20 (20)






Abbrebiations: IFN-α interferon-α, TKI tyrosine kinase inhibitor, mTORI
mTOR inhibitor
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Interventions
After evaluation by PET/CT, 40 patients were treated
with sorafenib, 38 with sunitinib, 12 with interferon-α
(IFN-α), eight with temsirolimus, one with axitinib, one
with pazopanib, and one with chemotherapy. Compre-
hensive decisions regarding first interventions were
made from pathological and clinical information before
the FDG PET/CT evaluation.
The median observation period was 18 months (range
1–70). During the observation period, 44 patients were
treated with a single intervention (20 sorafenib, 19 suni-
tinib, four IFN-α, and one temsirolimus), 22 with two in-
terventions (10 TKI to mTORI, 9 TKI to TKI, and 3
mTORI to TKI), 20 with three interventions, and 15
with more than three interventions. Ninety-six patients
were treated with TKI, 43 with mTORI, and 16 with
IFN-α. Six patients underwent metastasectomy, and five,
nephrectomy (Table 2). There were 57 cases of death
due to cancer; we confirmed that the other 44 patients
were still alive at the time of this writing. There were no
cases of death due to other causes.
Assessment by FDG PET/CT
The max SUVmax of all patients ranged from undetect-
able to 23.0 (median 6.9). When max SUVmax was ana-
lyzed as a continuous variable, high max SUVmax was
associated with shorter OS, (Fig. 1) (p < 0.001, hazard ra-
tio 1.257, 95 % confidence interval [CI] 1.177–1.342).
The impact of max SUVmax on OS was compared
with that of numerous standard risk factors. The multi-
variate analysis of max SUVmax with performance sta-
tus, LDH, corrected calcium, interval between diagnosis
and entry, and pathology (p < 0.05 in univariate analysis)
revealed that max SUVmax was a significant independ-
ent predictor of survival (Table 3).
At first, we validated the application of a cutoff of max
SUVmax of 8.8, which was the same cutoff point for OS
prediction used in our previous report [13], focusing on
the 77 patients who were enrolled after the preliminary
analysis. The median OS of the 52 patients with RCC
having a max SUVmax < 8.8 was 57.3 months, and that
of the 25 patients with RCC having the max SUVmax ≥
8.8 was 13.2 months (95 % CI 5.89–20.51) (p < 0.0001)
(Fig. 2).
We then divided the 101 patients into three subgroups
by max SUVmax. Because the existence of the subgroup
of patients with RCC showing very high max SUVmax
whose survival time were less than 1 year became appar-
ent in Fig. 1. The max SUVmax of 51 patients (50 %)
was < 7.0 and the median OS of this subgroup was
41.9 months (95 % CI 34.12–49.68). The max SUVmax
of 32 patients (32 %) were ≥ 7.0 and < 12.0, and median
OS was 20.6 months (95 % CI 12.4–28.8). The max
Fig. 1 The association of pretreatment max SUVmax and survival.
The vertical axis plots the pretreatment max SUVmax of individual
patients, and the horizontal axis plots their survival. Open circles are
the patients who were alive on the last observation days and closed
circles are the patients dead as a result of cancer
Table 3 Univariate and multivariate Cox analyses of max SUVmax versus standard prognostic factors for advanced RCC
Univariate cox analyses Multivariate cox analyses
Risk Fcotr P value HR 95 % CI P value HR 95 % CI
max SUVmax (continuous variable) <0.001 1.257 1.177-1.342 <0.001 1.265 1.159-1.380
Karnofsky performance status (<80 %) 0.036 2.107 1.051–4.221 0.296 0.623 0.256–1.514
Lactate dehydrogenase
(>1.5x upper limit of normal)
<0.001 8.655 3.559–21.049 0.001 5.026 1.935–13.052
Corrected calcium (>10 mg/dl) 0.014 2.457 1.198–5.038 0.151 1.943 0.784–4.815
Hemoglobin (<lower limit of normal) 0.121 1.810 0.854–3.833
Interval from initial diagnosis to
treatment (<1 year)
0.014 1.937 1.142–3.286 0.164 1.549 0.836–2.870
Age (>65 years old) 0.416 0.803 0.474–1.361
Sex (male or female) 0.890 1.046 0.551–1.984
Pathology (clear or non–clear) 0.044 2.113 1.021–4.373 0.962 0.980 0.419–2.291
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SUVmax of 18 patients (18 %) was ≥ 12.0, and median OS
was 4.2 months (95 % CI 0.7–7.7). Differences in OS for
these patient subgroups were statistically significant (< 7.0
vs. ≥ 7.0 and < 12.0: p=0.0001, ≥ 7.0 and < 12.0 vs. ≥ 12.0:
p=0.0004) (Fig. 3).
Figure 4 presents the features of the FDG PET/CT
scans. Regardless of the tumor size and the organs where
the metastasis was located, the patients with lower max
SUVmax exhibited better OS than the patients with
higher max SUVmax.
Discussion
We demonstrated that max SUVmax by FDG PET/CT is
a useful prognostic marker for survival of patients with
advanced RCC. It is reasonable that RCCs with high max
SUVmax would have poorer prognoses because it has
been suggested that RCCs with rapid progression need
more glucose as an energy source and take up more FDG.
Numerous recent studies of various types of cancer, in-
cluding head-and-neck, lung, and cervical, have explored
the prognostic significance of the SUV [18–21]. Although
the size of our study was relatively small, the results were
more significant compared with these studies of other
malignancies. We propose two possible reasons for this
result. The first is that the prognosis of patients with ad-
vanced RCC can vary widely. Many researchers have been
trying to establish methods to predict the prognosis of
RCC. The MSKCC classification advocated by Motzer et
al. is most commonly used for prognosis [12], and they re-
ported median OS of favorable, intermediate, and poor
risk patients of 30, 14, and 5 months, respectively, when
the patients were divided into the three groups by five
clinical risk factors. The second reason why results may
have been more significant in our study was that the main
treatments were targeted molecular therapeutics, which
suppressed the biological activity of the cancer and the
original biological properties of RCC affected the clinical
courses markedly. We showed that the power of predic-
tion by max SUVmax was superior to that by the risk
factors used for MSKCC classification. It is meaningless,
however, to discuss whether evaluation by FDG PET/CT
or by clinical factors is better. We must focus on tailoring
treatment according to prognosis to lengthen OS.
FDG PET/CT has not been generally applied to evaluate
RCC owing to the urinary excretion of the radiotracer,
which can mask the presence of primary lesions [22, 23].
However we previously reported that FDG accumulation
was evaluable in 94.9 % of all RCC lesions diagnosed by
a CT scan except for lung or liver metastases < 1 cm,
providing combined morphological and functional infor-
mation [13]. These results were consistent with a previous
report [24]. Additionally, Majhail et al. proved the patho-
logical accuracy of diagnosis by FDG PET [25]. They
Fig. 2 Validation of the cutoff point used in the preliminary report.
We validated the usefulness of max SUVmax 8.8 [12], focusing on
the 77 patients who were enrolled after the preliminary analysis
Fig. 3 Overall survival curve of total 101 patients stratified by two cutoff points, max SUVmax 7.0 and 12.0
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performed biopsy or surgical resection of 36 distant
metastatic lesions in 24 patients and revealed that the
pathological positive predictive value of FDG PET/CT
was 100 %.
Recently, we and other researchers have reported
using FDG PET/CT to assess the response of RCC to
molecular-targeting therapies [14, 26–28]. This evalu-
ation is clinically beneficial because molecular-targeting
therapies, as opposed to classical cytotoxic anticancer
therapeutics, do not always cause obvious tumor shrink-
age. These studies have reported that the decrease of FDG
uptake predicted long-term dormancy of RCC, suggest-
ing that FDG uptake can be used not just as a prognos-
tic indicator before treatment, but also to assess the
real-time status of biological activity in RCC. When
more data about the assessment of RCC by FDG PET/
CT are accumulated in the future, the therapeutic strat-
egy of the individual patient with advanced RCC may
be decided based on the assessment by FDG PET/CT.
For example, the patients with RCC showing very high
max SUVmax will be treated with temsirolimus,, which
is an intravenous mTOR inhibitor currently recom-
mended for patients who are classified as “poor risk” by
clinical risk factors. In contrast, patients with RCC
showing low max SUVmax may be treated with more
flexibility, focusing on the quality of life with the care-
ful sequential assessment by FDG PET/CT.
Our study has several limitations. First, the patients
were treated with various therapies, including TKI,
mTORI, and IFN-α after evaluation by FDG PET/CT.
Second, the number of systematic treatments that the
patients enrolled in this study were subjected to were
variable. Third, five patients underwent nephrectomies
and six patients underwent metastasectomy, although the
purpose of these surgeries was not complete resection.
The pretreatment max SUVmax assessed by FDG
PET/CT can predict survival of patients with advanced
RCC. FDG PET/CT has the potential to provide helpful
information for clinical decision making. Future patho-
logical and molecular studies are needed to disclose the
biological means of FDG accumulation in RCC.
Conclusions
Pretreatment max SUVmax assessed by FDG PET/CT can
predict survival of patients with advanced RCC. FDG PET/
CT has the potential to be an “imaging biomarker,” provid-
ing helpful information for clinical decision making.
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